Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth

Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth is an Australian court decision that addresses several issues concerning the validity and scope of a patent related to a method and formulation for administering a drug, venlafaxine hydrochloride. The dispute primarily revolves around whether the patent claims are valid, sufficiently disclosed, and whether they infringe on any prior art. The case was heard in the Federal Court of Australia.

The legal issues at the heart of this case include the characterisation of the invention as disclosed in the priority document, the fair basis of the patent claims, and the validity of the patent in light of prior disclosures and technical limitations. Additionally, the court examined whether certain claims were sufficiently disclosed in the priority document, whether they were obvious, and if there were any false suggestions or misstatements that could affect the patent's validity.

In delivering the judgment, the court found that the claims of the patent were not fairly based on the priority document, as they extended beyond the specific formulation and method disclosed. The court emphasised that the priority document only disclosed a particular encapsulated formulation and a method associated with that formulation. The broader claims of the patent, which included methods for administering any extended-release formulation, were deemed to extend beyond the fair basis provided by the priority document. The court also noted that the specification contained statements about the impossibility of achieving certain formulations, which further constrained the scope of the invention. Consequently, the patent claims that went beyond the specific invention disclosed in the priority document were invalidated.

The court's decision ultimately led to the invalidation of certain patent claims due to their lack of fair basis in the priority document, and the court ordered the parties to submit proposed orders within a specified timeframe.